WO2020032258A1 - 多価不飽和脂肪酸を生産する微生物及び多価不飽和脂肪酸の製造法 - Google Patents
多価不飽和脂肪酸を生産する微生物及び多価不飽和脂肪酸の製造法 Download PDFInfo
- Publication number
- WO2020032258A1 WO2020032258A1 PCT/JP2019/031649 JP2019031649W WO2020032258A1 WO 2020032258 A1 WO2020032258 A1 WO 2020032258A1 JP 2019031649 W JP2019031649 W JP 2019031649W WO 2020032258 A1 WO2020032258 A1 WO 2020032258A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pufa
- domain
- microorganism
- genus
- protein
- Prior art date
Links
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 title claims abstract description 176
- 244000005700 microbiome Species 0.000 title claims abstract description 147
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 238
- 230000000694 effects Effects 0.000 claims abstract description 73
- 230000037353 metabolic pathway Effects 0.000 claims abstract description 41
- -1 3-hydroxyhexanoyl Chemical group 0.000 claims abstract description 33
- 102000004867 Hydro-Lyases Human genes 0.000 claims abstract description 4
- 108090001042 Hydro-Lyases Proteins 0.000 claims abstract description 4
- 101710146995 Acyl carrier protein Proteins 0.000 claims abstract description 3
- 108010030975 Polyketide Synthases Proteins 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 27
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 22
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 19
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 17
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 14
- 241000863430 Shewanella Species 0.000 claims description 9
- 241000233675 Thraustochytrium Species 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 241000607568 Photobacterium Species 0.000 claims description 7
- 108700016155 Acyl transferases Proteins 0.000 claims description 6
- 102000057234 Acyl transferases Human genes 0.000 claims description 6
- 241001306132 Aurantiochytrium Species 0.000 claims description 6
- 241001135744 Colwellia Species 0.000 claims description 6
- 241000235070 Saccharomyces Species 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 241000588722 Escherichia Species 0.000 claims description 5
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 claims description 5
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 claims description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 4
- 241001491678 Ulkenia Species 0.000 claims description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 4
- 241000003610 Aplanochytrium Species 0.000 claims description 3
- 241001460992 Aureispira marina Species 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 241000186216 Corynebacterium Species 0.000 claims description 3
- 241001491670 Labyrinthula Species 0.000 claims description 3
- 241000592260 Moritella Species 0.000 claims description 3
- 241000235648 Pichia Species 0.000 claims description 3
- 102000004357 Transferases Human genes 0.000 claims description 3
- 108090000992 Transferases Proteins 0.000 claims description 3
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 2
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 claims description 2
- 241001138695 Parietichytrium Species 0.000 claims description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 claims description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 claims description 2
- 241000235013 Yarrowia Species 0.000 claims description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 2
- 235000021342 arachidonic acid Nutrition 0.000 claims description 2
- 229940114079 arachidonic acid Drugs 0.000 claims description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 108010019608 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase Proteins 0.000 claims 1
- 102100037149 3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial Human genes 0.000 claims 1
- 101710198510 Enoyl-[acyl-carrier-protein] reductase [NADH] Proteins 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 101710142619 3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 161
- 102000004169 proteins and genes Human genes 0.000 description 161
- 108020004414 DNA Proteins 0.000 description 91
- 238000000034 method Methods 0.000 description 50
- 241000588724 Escherichia coli Species 0.000 description 49
- 150000001413 amino acids Chemical group 0.000 description 30
- 239000012634 fragment Substances 0.000 description 28
- 108091008146 restriction endonucleases Proteins 0.000 description 27
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 22
- 230000006870 function Effects 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 150000004665 fatty acids Chemical class 0.000 description 11
- 229960005322 streptomycin Drugs 0.000 description 11
- 239000013598 vector Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 229930027917 kanamycin Natural products 0.000 description 9
- 229960000318 kanamycin Drugs 0.000 description 9
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 9
- 229930182823 kanamycin A Natural products 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 229960000723 ampicillin Drugs 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 8
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 125000005907 alkyl ester group Chemical group 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 241000205145 Desulfobacterium Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 5
- 229940033080 omega-6 fatty acid Drugs 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 4
- WIIZWVCIJKGZOK-IUCAKERBSA-N 2,2-dichloro-n-[(1s,2s)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide Chemical compound ClC(Cl)C(=O)N[C@@H](CO)[C@@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-IUCAKERBSA-N 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 229910015900 BF3 Inorganic materials 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 102000008300 Mutant Proteins Human genes 0.000 description 4
- 108010021466 Mutant Proteins Proteins 0.000 description 4
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 241000003595 Aurantiochytrium limacinum Species 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 101710160066 Mitochondrial holo-[acyl-carrier-protein] synthase Proteins 0.000 description 3
- 241001260361 Photobacterium profundum Species 0.000 description 3
- 241000598397 Schizochytrium sp. Species 0.000 description 3
- 241001538194 Shewanella oneidensis MR-1 Species 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- XQFCCTPWINMCQJ-UHFFFAOYSA-N 1-(1H-indol-3-yl)-N,N-dimethylpropan-2-amine Chemical compound CC(N(C)C)CC1=CNC2=CC=CC=C12 XQFCCTPWINMCQJ-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 241000186146 Brevibacterium Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000186226 Corynebacterium glutamicum Species 0.000 description 2
- 241000199913 Crypthecodinium Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 241001627083 Desulfatibacillum Species 0.000 description 2
- 241000605829 Desulfococcus Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- 241001135750 Geobacter Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241001467578 Microbacterium Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 2
- 241000233671 Schizochytrium Species 0.000 description 2
- 241000546140 Stigeoclonium Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000144181 Thraustochytrium aureum Species 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 241000186254 coryneform bacterium Species 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 101150098466 rpsL gene Proteins 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- YOFPFYYTUIARDI-ZCFIWIBFSA-N (2r)-2-aminooctanedioic acid Chemical group OC(=O)[C@H](N)CCCCCC(O)=O YOFPFYYTUIARDI-ZCFIWIBFSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical group [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101100411566 Arabidopsis thaliana RABA1A gene Proteins 0.000 description 1
- 101100467422 Arabidopsis thaliana RABA5E gene Proteins 0.000 description 1
- 101100411656 Arabidopsis thaliana RABE1C gene Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000030853 Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241001130339 Aurantiochytrium sp. Species 0.000 description 1
- 241001460991 Aureispira Species 0.000 description 1
- 241000589151 Azotobacter Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000636159 Candidatus Solibacter usitatus Ellin6076 Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 239000005746 Carboxin Substances 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000200138 Ceratium Species 0.000 description 1
- 239000004970 Chain extender Substances 0.000 description 1
- 241001325292 Chitinophaga Species 0.000 description 1
- 241000237645 Chitinophaga pinensis DSM 2588 Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241001491656 Chrysochromulina Species 0.000 description 1
- 241000206751 Chrysophyceae Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000412846 Colwellia psychrerythraea 34H Species 0.000 description 1
- 241001517047 Corynebacterium acetoacidophilum Species 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- 241000807905 Corynebacterium glutamicum ATCC 14067 Species 0.000 description 1
- 241000195618 Cryptomonas Species 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000764785 Desulfobacterium autotrophicum HRM2 Species 0.000 description 1
- 241000383790 Desulfococcus oleovorans Hxd3 Species 0.000 description 1
- 241001221643 Diacronema Species 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- 241000391095 Dinobryon Species 0.000 description 1
- 241000199914 Dinophyceae Species 0.000 description 1
- 241000196133 Dryopteris Species 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241001058146 Erium Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001452028 Escherichia coli DH1 Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 241000195620 Euglena Species 0.000 description 1
- 241000195619 Euglena gracilis Species 0.000 description 1
- 241000195623 Euglenida Species 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000623913 Geobacter bemidjiensis Bem Species 0.000 description 1
- 241001338085 Gloeobacter violaceus PCC 7421 Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710150242 Glutamate decarboxylase A Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010043428 Glycine hydroxymethyltransferase Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000866505 Gyrodinium Species 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000003482 Japonochytrium Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000144155 Microbacterium ammoniaphilum Species 0.000 description 1
- 241000192701 Microcystis Species 0.000 description 1
- 241000488294 Microcystis aeruginosa NIES-843 Species 0.000 description 1
- 101001014220 Monascus pilosus Dehydrogenase mokE Proteins 0.000 description 1
- 241000294598 Moritella marina Species 0.000 description 1
- 241000159660 Nannochloropsis oculata Species 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241000192656 Nostoc Species 0.000 description 1
- 241000894763 Nostoc punctiforme PCC 73102 Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- KNTFCRCCPLEUQZ-VKHMYHEASA-N O-methylserine Chemical compound COC[C@H](N)C(O)=O KNTFCRCCPLEUQZ-VKHMYHEASA-N 0.000 description 1
- 241000199478 Ochromonas Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 1
- 241000200172 Oxyrrhis Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101150072307 PS gene Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 101000573542 Penicillium citrinum Compactin nonaketide synthase, enoyl reductase component Proteins 0.000 description 1
- 102000008153 Peptide Elongation Factor Tu Human genes 0.000 description 1
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 1
- 241000199911 Peridinium Species 0.000 description 1
- 241000589952 Planctomyces Species 0.000 description 1
- 241001031744 Planctopirus limnophila DSM 3776 Species 0.000 description 1
- 241000593473 Platychrysis Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241001491792 Prymnesium Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 241001647888 Psychroflexus Species 0.000 description 1
- 241001256940 Psychroflexus torquis ATCC 700755 Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000186813 Renibacterium Species 0.000 description 1
- 241000853548 Renibacterium salmoninarum ATCC 33209 Species 0.000 description 1
- 101710088839 Replication initiation protein Proteins 0.000 description 1
- 241001501882 Rhodomonas Species 0.000 description 1
- 241001170740 Ruminiclostridium thermocellum ATCC 27405 Species 0.000 description 1
- 241000187560 Saccharopolyspora Species 0.000 description 1
- 241000634742 Saccharopolyspora erythraea NRRL 2338 Species 0.000 description 1
- 241000233673 Schizochytrium aggregatum Species 0.000 description 1
- 241000003597 Schizochytrium minutum Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000019394 Serine hydroxymethyltransferases Human genes 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000881765 Serratia ficaria Species 0.000 description 1
- 241000218654 Serratia fonticola Species 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000878021 Shewanella baltica Species 0.000 description 1
- 241001617021 Shewanella livingstonensis Species 0.000 description 1
- 241001275824 Shewanella pneumatophori Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241001532577 Sorangium Species 0.000 description 1
- 241000862997 Sorangium cellulosum Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241001466451 Stramenopiles Species 0.000 description 1
- 241000817756 Thraustochytrium roseum Species 0.000 description 1
- 241001298230 Thraustochytrium sp. Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 101150050575 URA3 gene Proteins 0.000 description 1
- 101150044776 URA5 gene Proteins 0.000 description 1
- 241001298226 Ulkenia sp. Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241001660687 Xantho Species 0.000 description 1
- 241000206764 Xanthophyceae Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- GYSSRZJIHXQEHQ-UHFFFAOYSA-N carboxin Chemical compound S1CCOC(C)=C1C(=O)NC1=CC=CC=C1 GYSSRZJIHXQEHQ-UHFFFAOYSA-N 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- BBJIPMIXTXKYLZ-UHFFFAOYSA-N isoglutamic acid Chemical compound OC(=O)CC(N)CC(O)=O BBJIPMIXTXKYLZ-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- KYOBSHFOBAOFBF-XVFCMESISA-N orotidine 5'-phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1C(O)=O KYOBSHFOBAOFBF-XVFCMESISA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1288—Transferases for other substituted phosphate groups (2.7.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
- C12Y103/01—Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
- C12Y103/01009—Enoyl-[acyl-carrier-protein] reductase (NADH) (1.3.1.9)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01038—[Acyl-carrier-protein] S-acetyltransferase (2.3.1.38)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01041—Beta-ketoacyl-acyl-carrier-protein synthase I (2.3.1.41)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/08—Transferases for other substituted phosphate groups (2.7.8)
- C12Y207/08007—Holo-[acyl-carrier-protein] synthase (2.7.8.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Definitions
- the present invention relates to a microorganism producing polyunsaturated fatty acid (PUFA) and a method for producing PUFA using the microorganism.
- PUFA polyunsaturated fatty acid
- DHA docosahexaenoic acid
- EPA eicosapentaenoic acid
- ARA arachidonic acid
- DPA docosapentaenoic acid
- PUFAs polyunsaturated fatty acids
- PUFA is known to have various physiological functions such as prevention of arteriosclerosis and hyperlipidemia (Non-Patent Documents 1 and 2).
- PUFAs have ⁇ 3 fatty acids such as DHA and EPA, ⁇ 6 fatty acids such as DPA and ARA, and double bonds first introduced at the ninth carbon, depending on the position of the double bond from the methyl terminal in the molecule. They can be classified into ⁇ 9 fatty acids, ⁇ 11 fatty acids in which a double bond is first introduced into the eleventh carbon, and the like.
- PUFA-PKS polyunsaturated fatty acid polyketide synthase
- the anaerobic pathway by PUFA-PKS is a pathway for synthesizing PUFA from acetyl-CoA or malonyl-CoA, and some marine bacteria and eukaryotes of Labyrinthura may have a pathway for producing DHA and EPA. It is known (Non-Patent Documents 4 and 5).
- an ARA production system for example, an ARA production system of Aureispira @ marina is known (Non-Patent Document 6).
- PUFA-PKS is a complex enzyme composed of a plurality of proteins (hereinafter, also referred to as a protein complex), and each protein has a plurality of functional domains related to the synthesis of PUFA.
- Functional domains present in PUFA-PKS include ⁇ -ketoacyl-acyl carrier protein synthase domain (hereinafter referred to as KS domain) and phosphopantetheinyl group, which are considered to be involved in the condensation of malonyl-ACP and acyl-ACP.
- KS domain ⁇ -ketoacyl-acyl carrier protein synthase domain
- phosphopantetheinyl group which are considered to be involved in the condensation of malonyl-ACP and acyl-ACP.
- An acyl carrier protein domain (hereinafter, referred to as an ACP domain) which is supposed to function as a site for fatty acid synthesis by bonding to an acyl group via a thioester bond, and a ketoreductase domain which is supposed to reduce a carbonyl group generated by condensation (
- a KR domain a DH domain that is supposed to form a double bond by dehydrating a hydroxyl group generated by the KR domain, and a chain elongation factor domain that is involved in carbon chain elongation
- ER domain Enoyl reductase domain
- AT domain an acyltransferase domain
- AT domain malonyl-CoA: acyltransferase domain (hereinafter, referred to as AT domain).
- MAT domain MAT domain
- PPT domain phosphopantethein transferase domain
- Patent Document 1 As a method of industrially producing ARA, a method of isolating ARA from mold biomass (Patent Document 1) is known. However, there is a problem that there are many by-products of unsaturated fatty acids other than the objective, and efficient ARA is produced. There was a need for a production method.
- PUFA-PKS produces different types of PUFA depending on the type. For example, Schizochyrium @ sp. Aurantiochytrium @ sp. And PUFA-PKS derived from Moritela @ marina, DHA, PUFA-PKS derived from Shewanella @ oneidensis and Photobacterium @ profundum, EPA, and Aureispira @ marina produced mostly as PU, and almost no ARA was produced as PU. Or, even if it is produced, it is small compared to the main product.
- Non-Patent Documents 4 and 7 discuss cloning of the PUFA-PKS gene from bacteria of the genus Shewanella and eukaryotes of stramenopiles, expression in a heterologous organism, and production of PUFA.
- Non-Patent Document 8 a study using the pfaB gene that is a constituent gene of PUFA-PKS derived from Moritella marina that produces DHA and a pfaB gene that constitutes PUFA-PKS derived from Shewanella pneumatophori that produces EPA have been conducted. It is disclosed that the pfaB gene encoding the domain is involved in the type of PUFA produced.
- Non-Patent Document 9 discloses that introduction of the DH domain of PUFA-PKS derived from the genus Thraustochytrium into Escherichia coli increases the production of fatty acids and the proportion of unsaturated fatty acids.
- PU As a conventional PUFA production system using PUFA-producing microorganisms, for example, there is an ARA production system using microorganisms described in Non-Patent Document 6, but the ARA productivity by the ARA production system is not sufficient at an industrial level. Further, the method of isolating ARA from mold biomass as in the method described in Patent Document 1 has a problem that there are many by-products of unsaturated fatty acids other than the target.
- an object of the present invention is to provide a microorganism that efficiently produces PUFA and a method for producing PUFA using the microorganism.
- a microorganism capable of producing PUFA into which a gene encoding a foreign PS-DH domain, which has a higher activity against 3-hydroxyhexanoyl ACP than a native FabA-DH domain, has been introduced into a microorganism having a metabolic pathway called PUFA.
- PUFA a microorganism having a metabolic pathway
- the microorganism having a PUFA metabolic pathway is a microorganism having an ⁇ 3 PUFA metabolic pathway, and the PUFA that can be produced is ⁇ 6 PUFA.
- microorganisms having a PUFA metabolic pathway include the genus Shewanella, the genus Photobacterium, the genus Moritella, the genus Colwellia, the genus Aurantiochytrium, the genus Thraustochytrium, and Thraustochytrium.
- a microorganism capable of producing PUFA wherein a microorganism having no PUFA metabolic pathway is introduced with a gene encoding each domain described in the following (a) to (j) having PUFA-PKS activity, wherein PS- A microorganism in which the DH domain exhibits higher activity against 3-hydroxyhexanoyl ACP than the FabA-DH domain.
- KS domain b) MAT domain
- ACP domain d
- KR domain e
- PS-DH domain f
- CLF domain g) AT domain
- FabA-DH domain i
- ER domain j) PPT domain 6.
- microorganism according to 5 above which has all the PUFA synthesis genes of the microorganism capable of producing the PUFA according to any one of 1 to 4 above. 7.
- the microorganism according to 5 or 6, wherein the PUFA that can be produced is ⁇ 6 PUFA.
- the microorganism according to any one of the above items 5 to 7, wherein the PUFA that can be produced is ARA or DPA.
- Microorganisms that do not have a PUFA metabolic pathway include the genus Escherichia, the genus Bacillus, the genus Corynebacterium, the genus Yarrowia, the genus Saccharomyces, or the genus Candida or Candida.
- a microorganism capable of producing PUFA wherein a microorganism having no PUFA metabolic pathway is transfected with a gene encoding each of the following domains (a) to (j) having PUFA-PKS activity: , A microorganism in which the PS-DH domain exhibits higher activity against 3-hydroxyhexanoyl ACP than the FabA-DH domain.
- A) KS domain (b) MAT domain (c) ACP domain (d) KR domain (e) PS-DH domain (f) CLF domain (g) AT domain (h) FabA-DH domain (i) ER domain ( j) PPT domain
- the microorganism of the present invention is characterized in that, in a microorganism capable of producing PUFA, a PS-DH domain gene having a higher activity for a fatty acid substrate, 3-hydroxyhexanoyl @ ACP, than a FabA-DH domain has been introduced,
- the reactivity of PS-DH domain to 3-hydroxyhexanoyl @ ACP in the microorganism is relatively higher than that of FabA-DH domain, so that a target PUFA or a PUFA-containing composition can be efficiently produced.
- PUFA can be produced at low cost and with high efficiency, and can be applied to production of PUFA at an industrial level.
- FIG. 1 shows a schematic diagram of a protein constituting PUFA-PKS and a domain structure thereof in various microorganisms.
- polyunsaturated fatty acid refers to a long-chain fatty acid having a carbon chain length of 18 or more and an unsaturated bond number of 2 or more.
- domain refers to a part consisting of a continuous amino acid sequence in a protein, and is a region having a specific biological activity or function in the protein.
- PUFA-PKS has the same meaning as PUFA @ synthase.
- PUFA @ synthase is a group of enzymes that synthesize specific long-chain unsaturated fatty acids using malonyl-CoA or the like as a carbon source, and includes KS, MAT, ACP, KR, PS-DH, CLF, AT, FabA-DH. , ER, and PPTase domains (ACOS Lipid Library: PUFA synthase; Science, 2001, 293, 290-293; PLoS One, 2011, 6, e20146, etc.).
- KS domain is a domain of a protein constituting a protein complex having PUFA-PKS activity, and refers to a domain involved in the condensation of malonyl ACP and acyl ACP.
- the MAT domain and AT domain are domains of a protein constituting a protein complex having PUFA-PKS activity, and refer to domains involved in acyl group transfer.
- the ACP domain is a domain of a protein constituting a protein complex having PUFA-PKS activity.
- the ACP domain binds to an acyl group via a phosphopantetheinyl group via a thioester bond, and functions as a place of fatty acid synthesis. -Refers to domains essential for PKS activity.
- KR domain is a domain of a protein constituting a protein complex having PUFA-PKS activity, and refers to a domain involved in reduction of a ketone group generated by condensation.
- PS-DH domain and FabA-DH domain which are DH domains, are domains of a protein constituting a protein complex having PUFA-PKS activity, and are domains involved in dehydration of a hydroxyl group generated by reducing a ketone group.
- the CLF domain is a domain of a protein constituting a protein complex having PUFA-PKS activity, and refers to a domain involved in carbon chain elongation.
- the ER domain is an acyltransferase domain
- the malonyl-CoA: ACP acyltransferase domain is a domain of a protein constituting a protein complex having PUFA-PKS activity and is a domain involved in acyl group transfer.
- PPTase is an enzyme that constitutes a protein complex having PUFA-PKS activity, and refers to an enzyme involved in activation of the ACP domain.
- cognate means that when a certain protein is allowed to coexist with another protein, a specific reaction is integrally performed.
- the term “cooperate” is necessary for PUFA-PKS activity. This means that when a plurality of domains coexist, they exhibit PUFA-PKS activity together with other domains.
- the term “foreign” refers to a substance that is not endogenous but derived from a heterologous substance. If the host organism before transformation does not have the gene to be introduced according to the present invention, it is encoded by the gene. When the protein according to the present invention is substantially not expressed, or when the amino acid sequence of the protein is encoded by a different gene but the activity of the endogenous protein is not expressed after the transformation, the gene according to the present invention is introduced into the host organism. Used to mean to do.
- the term “host organism” refers to an original organism to be subjected to genetic modification, transformation, and the like.
- the original organism to be transformed by gene transfer is a microorganism, it is also referred to as a parent strain or a host strain.
- microorganisms examples include the following microorganisms (1) and (2).
- (2) Genes encoding KS, MAT, ACP, KR, PS-DH, CLF, AT, FabA-DH, ER, and PPTase domains having PUFA-PKS activity are added to microorganisms having no PUFA metabolic pathway.
- a microorganism having a PUFA metabolic pathway refers to a microorganism having a PUFA-producing ability by nature.
- Examples of microorganisms having the PUFA metabolic pathway include the genus Shewanella, the genus Photobacterium, the genus Moritela, the genus Colwellia, the genus Aurantiochytrium, and the Thraustochytrium.
- a microorganism having an ⁇ 3 PUFA metabolic pathway is preferable, and examples thereof include a microorganism having a DHA metabolic pathway and a microorganism having an EPA metabolic pathway.
- microorganisms having a DHA metabolic pathway include microorganisms of the genus Moritela, Colwellia, Aurantiochytrium, Thraustochytrium, and Schizochytrium. .
- Moritela Marina Preferably, Moritela Marina, Colwellia cyclerythraea, Aurantiochytrium limacinum, Thraustochyura aureum such as Thraustochyura aureum such as Thraustochytrium aureum such as Aurantiochytrium limacinum
- the present invention is not limited thereto.
- microorganism having the DHA metabolic pathway a microorganism belonging to the genus Aurantiochytrium is preferable, and examples thereof include Aurathiochitrium @ SP @ OH4 strain (accession number FERM @ BP-11524) and the like, and mutants thereof. Microorganisms having the ability to produce DHA may be used.
- the Aurantiochytrium sp. OH4 strain was deposited under the Patent Microorganisms Depositary of the National Institute of Technology and Evaluation (NITE), located at 1-1, Higashi 1-1, Tsukuba, Ibaraki, Japan, postcode 305-8566. Deposited at the center.
- the date of receipt (deposit date) is January 11, 2013 (AD 2013), and the deposit number is FERM @ BP-11524.
- microorganisms having an EPA metabolic pathway include microorganisms of the genus Shewanella, the genus Photobacterium, and the genus Vibrio.
- Shewanella oneidenissis, Shewanella livingstonensis, Shewanella baltica, Shewanella photobala, Shewanella pearanab, etc. are not limited as long as they have an EPA metabolic pathway.
- a microorganism that does not have a PUFA metabolic pathway refers to a microorganism that does not naturally have a PUFA-producing ability.
- Microorganisms that do not have a PUFA metabolic pathway include, for example, bacteria, microalgae, fungi, protists, and protozoa.
- bacteria examples include, for example, genus Escherichia, genus Serratia, genus Bacillus, genus Brevibacterium, genus Corynebacterium, genus Microbacterium, and genus Microbacterium. Pseudomonas) and microorganisms belonging to the genus selected from the group consisting of Aureispira.
- Escherichia coli XL1-Blue Escherichia coli XL2-Blue
- Escherichia coli DH1 Escherichia coli MC1000
- Escherichia coli KY3276 Escherichia coli W1485, Escherichia coli JM109, Escherichia coli HB101
- microalgae examples include, for example, Euglenophyceae (Euglena genus [and Peranema genus), green algae (Chrysophyceae) [eg, Ochromonas genus (Chrysaceae), Dacenaea (Yasaunab)
- Euglenophyceae Euglena genus [and Peranema genus
- green algae Chrysophyceae
- Dacenaea Yasaunab
- the genus Dinobryon, the genus Platychrysis and the genus Chrysochromulina the Dinophyceae (eg, the genus Crypthecodinium, gym, gymium, gym, gym, and gym)
- Genus Peridinium genus Ceratium, Giroji Genus Gyrodinium and Oxyrrhis
- Genus [and flagellate lysochlorides (Rhizochloridaceae) and Afanocaete pascheri (Aphanochaete @ pascheri), Bumileria stigeoclonium (Bumilliaria stigeoclonium) and Baukeria Geminata (A. auger germia germophile) in the spores of A. Algae that produce an amoebic phase such as Species], Euthygmatophyceae, and Pymnesiopyceae (including, for example, the genus Prymnesium and Diacronema).
- ⁇ ⁇ ⁇ ⁇ Preferred species within these genera are not particularly limited, but include Nannochloropsis oculata, Crypthecodinium cohniii, and Euglena gracilis.
- fungi examples include yeasts of the genus Saccharomyces (Saccharomyces cerevisiae, Saccharomyces ⁇ ⁇ cerevisiae, Saccharomyces ⁇ karsbergensis, Saccharomyces karsbergensis), and genus of the genus Circa wiardia or Yardia darica (Y.
- yeasts such as the genus (Pichia), the genus Kluyveromyces, or other fungi, for example, filamentous fungi such as the genus Aspergillus, the genus Neurospora, the genus Penicillium. And the like.
- the microorganism (2) is preferably a microorganism into which all of the PUFA synthesis genes of the microorganism (1) have been introduced, that is, a microorganism having all of the PUFA synthesis genes of the microorganism (1).
- “activity against 3-hydroxyhexanoyl ACP” is an activity that acts preferentially on 3-hydroxyhexanoyl ACP, and more specifically, reactivity (affinity) with 3-hydroxyhexanoyl ACP.
- the activity against 3-hydroxyhexanoyl @ ACP can be measured by a method for evaluating the reverse reaction (hydroxylation reaction) of dehydratase.
- a product obtained by adding a protein containing a FabA-DH domain or a PS-DH domain is subjected to HPLC.
- the amount of the product (the product when using crotonyl @ ACP as a substrate: 3-hydroxy-butyryl-ACP, the product when using 2-trans-hexenoyl @ ACP as a substrate: 3 -Hydroxy-hexanoyl-ACP).
- the activity of the PS-DH domain for 3-hydroxyhexanoyl @ ACP is FabA-DH. It is judged that the activity is higher than that of the domain.
- the PS-DH domain exhibits a higher activity for 3-hydroxyhexanoyl ACP than the FabA-DH domain specifically means, for example, that the peak of the HPLC reacted under the following reaction conditions is 2 It is preferable that the height of the HPLC peak for the product using -trans-hexenoyl @ ACP as a substrate is 1.5 times or more, and more preferably, the height of the HPLC peak for the product using Crotonyl @ ACP as a substrate. Is 2 times or more, more preferably 5 times or more.
- reaction conditions A mixture of 80 mM Tris-HCl, 80 mM NaCl, 25 mM MgCl 2 , 100 ⁇ M ACP serving as a substrate, 20 ⁇ M Sfp, and 300 ⁇ M acyl-CoA, and reacted at 20 ° C. for 10 minutes was mixed with a PS-DH domain and a FabA-DH domain. Is added at 1 ⁇ M or 5 ⁇ M, and reacted at 20 ° C. Samples are collected at 1, 5, 10, 30, and 60 minutes after the start of the reaction, and subjected to LC / MS analysis to analyze the height of the HPLC peak.
- the term “Sfp” means 4′-phosphopantheinyl transferase derived from Bacillus subtilis.
- the activity of the endogenous PS-DH domain on 3-hydroxyhexanoyl @ ACP in the microorganism having the PUFA metabolic pathway is equal to or less than that of the endogenous FabA-DH domain.
- the PS-DH domain 3-hydroxyhexanoyl @ ACP in the microorganism is introduced. Is a microorganism having a relatively high reactivity as compared with the FabA-DH domain.
- the PS-DH domain is a FabA-DH domain.
- FabA-DH domain By having a higher activity against 3-hydroxyhexanoyl @ ACP, a microorganism having a higher reactivity of PS-DH domain to 3-hydroxyhexanoyl @ ACP in the microorganism as compared to the FabA-DH domain is obtained.
- the relatively high reactivity of the PS-DH domain to 3-hydroxyhexanoyl @ ACP in the microorganism compared to the FabA-DH domain makes the PS-DH domain more susceptible to the PUFA metabolic pathway of the microorganism than the FabA-DH domain.
- PUFA is produced through a PUFA biosynthetic pathway in which the PS-DH domain functions.
- the ⁇ 3 PUFA biosynthesis pathway in which the FabA-DH domain functions and the ⁇ 6 PUFA biosynthesis pathway in which the PS-DH domain functions Is mentioned.
- the PS-DH domain functions When the position of the double bond counted from the terminal carbon atom in the PUFA obtained in the PUFA biosynthetic pathway in which the FabA-DH domain functions is the ⁇ ( ⁇ ) position (eg, ⁇ 3 position), the PS-DH domain functions In the PUFA obtained by the PUFA biosynthesis pathway, the position of the double bond counted from the terminal carbon atom is the ⁇ ( ⁇ + 3) position (for example, the ⁇ 6 position).
- a 3-hydroxyhexanoyl ACP higher than the endogenous FabA-DH domain By introducing a gene encoding an exogenous PS-DH domain having an activity against E. coli, the reactivity of PS-DH domain to 3-hydroxyhexanoyl @ ACP in the microorganism is relatively higher as compared to FabA-DH domain. Become. As a result, the PS-DH domain acts preferentially on the 3-hydroxyhexanoyl @ ACP over the FabA-DH domain, resulting in a microorganism capable of producing ⁇ 6 PUFA as an end product.
- PS-DH domain a protein having the amino acid sequence represented by SEQ ID NO: 2 (encoded by the base sequence represented by SEQ ID NO: 136) on AraB derived from Aureispira marina Or a PS-DH domain on pfaB derived from Psychroflexus @ torquis [a protein having the amino acid sequence represented by SEQ ID NO: 137 (encoded by the nucleotide sequence represented by SEQ ID NO: 139)], and derived from Aureispira @ marina
- SEQ ID NO: 137 encoded by the nucleotide sequence represented by SEQ ID NO: 139
- the PS-DH domain on araB is preferred.
- sequences are known and can be used as appropriate.
- the PS-DH domain used in the present invention preferably includes the following.
- a protein having the amino acid sequence represented by SEQ ID NO: 2 or 137 [2] In the amino acid sequence represented by SEQ ID NO: 2 or 137, 1 to 20, preferably 1 to 10, most preferably A mutant protein preferably comprising an amino acid sequence in which 1 to 5 amino acids have been deleted, substituted or added, and having an activity against 3-hydroxyhexanoyl ACP [3] The amino acid sequence represented by SEQ ID NO: 2 or 137 And a homologous protein having an identity of at least 95% or more, preferably 97% or more, more preferably 98% or more, and most preferably 99% or more, and having activity against 3-hydroxyhexanoyl ACP.
- the gene encoding a PS-DH domain may be introduced into a microorganism by introducing a gene encoding a protein having a PS-DH domain into the microorganism.
- the protein having the PS-DH domain include AraB derived from Aureispira @ marina [protein having the amino acid sequence represented by SEQ ID NO: 58 (encoded by the nucleotide sequence represented by SEQ ID NO: 57)], and PfaB derived from Psychroflexus @ torquis [Protein having the amino acid sequence represented by SEQ ID NO: 138 (encoded by the base sequence represented by SEQ ID NO: 140)].
- the protein having a PS-DH domain used in the present invention preferably includes the following.
- a protein having the amino acid sequence represented by SEQ ID NO: 58 or 138 [5] In the amino acid sequence represented by SEQ ID NO: 58 or 138, 1 to 20, preferably 1 to 10, most preferably Preferably, the mutant protein comprises an amino acid sequence in which 1 to 5 amino acids have been deleted, substituted or added, and has an activity against 3-hydroxyhexanoyl ACP [6]
- the amino acid sequence represented by SEQ ID NO: 58 or 138 And at least 95% or more, preferably 97% or more, more preferably 98% or more, and most preferably 99% or more, and a homologous protein having activity against 3-hydroxyhexanoyl ACP.
- the protein having the amino acid sequence represented by SEQ ID NO: 58 is a protein consisting of 801 amino acid residues, and has a PS-DH domain at 531-790 residues from the N-terminal side.
- a mutant protein refers to a protein obtained by artificially deleting or substituting amino acid residues in the original protein or adding amino acid residues to the protein.
- deletion, substitution, insertion or addition of an amino acid refers to 1 to 20, preferably 1 to 10, and most preferably 1 to 5 amino acids at any position in the same sequence. May be deleted, substituted or added.
- the amino acid to be deleted, substituted or added may be of natural type or non-natural type.
- natural amino acids include L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-arginine, L-arginine, -Methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine and L-cysteine.
- amino acids included in the same group can be substituted for each other.
- Amino acids included in the same group can be substituted for each other.
- Group A leucine, isoleucine, norleucine, valine, norvaline, alanine, 2-aminobutanoic acid, methionine, O-methylserine, t-butylglycine, t-butylalanine, cyclohexylalanine
- B group aspartic acid, glutamic acid, isoaspartic acid, Isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid group
- C asparagine, glutamine group
- D lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid group
- E proline, 3 -Hydroxyproline, 4-hydroxyproline
- F group serine, threonine, homos
- a homologous protein is a protein in which the gene encoding the protein is considered to have the same evolutionary origin as the gene encoding the original protein because of similarity in structure and function to the original protein. Means a protein of an organism present in
- the gene encoding the PS-DH domain used in the present invention is not particularly limited as long as it encodes a protein having an activity against 3-hydroxyhexanoyl ACP, but is preferably a gene having any one of the following DNAs: No. [7] DNA encoding the protein of any one of the above [1] to [3] [8] DNA containing the base sequence represented by SEQ ID NO: 136 or SEQ ID NO: 139 [9] A DNA that hybridizes with a DNA consisting of a nucleotide sequence complementary to the DNA according to the above [7] or [8] under stringent conditions and encodes a homologous protein having an activity against 3-hydroxyhexanoyl ACP.
- [10] has at least 95% or more, preferably 97% or more, more preferably 98% or more, and most preferably 99% or more identity with the DNA sequence of the above-mentioned [7] or [8], DNA encoding a homologous protein having activity against 3-hydroxyhexanoyl ACP
- a gene encoding a protein having a PS-DH domain preferably, a gene having any one of the following DNAs is exemplified.
- DNA encoding the protein of any one of [4] to [6] above [12] DNA containing the base sequence represented by SEQ ID NO: 57 or SEQ ID NO: 140
- a homologous protein which hybridizes with a DNA consisting of a nucleotide sequence complementary to the nucleotide sequence of the DNA according to the above [11] or [12] under stringent conditions and has an activity against 3-hydroxyhexanoyl ACP.
- DNA encoding [14] It has at least 95% or more, preferably 97% or more, more preferably 98% or more, most preferably 99% or more identity with the DNA sequence of the above-mentioned [11] or [12], and Encoding a homologous protein having activity against 3-hydroxyhexanoyl ACP
- hybridize means that a DNA having a specific base sequence or a part of the DNA forms a complex complementarily with another DNA. Therefore, the DNA having the specific nucleotide sequence or a partial nucleotide sequence of the DNA is useful as a probe for Northern or Southern blot analysis or a DNA having a length that can be used as an oligonucleotide primer for PCR analysis. You may. Examples of DNA used as a probe include DNA having at least 100 bases or more, preferably 200 bases or more, and more preferably 500 bases or more. DNA used as a primer includes at least 10 bases or more, preferably 15 bases or more. DNA can be mentioned.
- DNA that hybridizes under stringent conditions can be obtained by following the instructions attached to a commercially available hybridization kit.
- commercially available hybridization kits include, for example, a random primed DNA labeling kit (manufactured by Roche Diagnostics) that prepares a probe by a random prime method and performs hybridization under stringent conditions.
- Stringent conditions include, for example, a filter on which DNA is immobilized and a probe DNA are combined with 50% formamide, 5 ⁇ SSC (750 mM sodium chloride, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), After incubating overnight at 42 ° C. in a solution containing 5 ⁇ Denhardt's solution, 10% dextran sulfate and 20 ⁇ g / l of denatured salmon sperm DNA, for example in a 0.2 ⁇ SSC solution at about 65 ° C. Can be used to wash the filter.
- 5 ⁇ SSC 750 mM sodium chloride, 75 mM sodium citrate
- 50 mM sodium phosphate pH 7.6
- the above various conditions can also be set by adding or changing a blocking reagent used to suppress the background of the hybridization experiment.
- the addition of the blocking reagents described above may involve changing the hybridization conditions to adapt the conditions.
- Examples of the DNA that can be hybridized under the above-mentioned stringent conditions include, for example, a base sequence of the target DNA of at least 95% when calculated based on the above parameters using the above-mentioned programs such as BLAST and FASTA.
- a DNA comprising a nucleotide sequence having an identity of preferably 97% or more, more preferably 98% or more, and most preferably 99% or more can be mentioned.
- the domains having PUFA-PKS activity to be introduced into microorganism (2) include KS domain, MAT domain, ACP domain, KR domain, CLF domain, AT domain, DH domain FabA-DH domain, ER domain and PPT. Domain.
- the respective domains are not limited as long as they cooperate to produce PUFA using acetyl-CoA as a starting substrate, and include, for example, each domain of known PUFA-PKS.
- the PUFA-PKS activity exhibited by the domains having PUFA-PKS activity introduced into the microorganism (2) cooperates to construct a microorganism transformed with a gene encoding each domain of PUFA-PKS, and It can be confirmed by culturing in a medium, producing and accumulating PUFA in the culture, and measuring the PUFA accumulated in the culture by gas chromatography.
- the “known PUFA-PKS” preferably refers to a genus Shewanella, a genus Colwellia, a genus Desulfatibacillum, a genus Psychroflexus, and a genus Psychroxium schichytrium.
- PKS more preferably Shewane la pealeana ATCC 700345, Shewanella oneidensis MR-1, Colwellia psychrerythraea 34H, Desulfatibacillum alkenivoransAK-01, Psychroflexus torquisATCC 700755, Schizochytrium sp.
- ATCC 20888 Nostoc punctiformePCC 73102, Microcystis aeruginosaNIES-843, Saccharopolyspora erythraea NRRL 2338, Geobacter bemidjiensis Bem, Planctomyces limnophilus DSM3776, Desulfococcus oleovorans Hxd3, Sorangium cellulosum 'Soce 56', Renibacterium salmoninarum ATCC 33209, Chitinophaga pinensisDSM 2588, Gloeobacter violaceusPCC 7421, Azot bacter vinelandiiDJ, Rhodococcus erythropolisPR4, Candidatus Solibacter usitatusEllin6076, Desulfobacterium autotrophicumHRM2, Clostridium thermocellumATCC 27405, Schizochytrium minutum, Schizochytrium sp.
- the microorganism selected from the group consisting of L1 @ ATCC @ 28207 originally contains PUFA-PKS, most preferably Shewanella @ pealeana @ ATCC $ 700345, Shewanella @ oneidensis @ MR-1, Colwellia @ psychrary @ rhya. .
- a microorganism selected from the group consisting of ATCC # 20888 can include PUFA-PKS which is originally possessed [FEMS @ Microbiol. Lett. (2009), Vol. 295, p170-176; PLoS @ ONE (2011), Vol. 6 (5), art. no. e20146].
- Table 1 shows examples of the amino acid sequence of each domain of the protein constituting PUFA-PKS and the amino acid sequence of each domain of the protein constituting the known PUFA-PKS used in Examples described later.
- the protein complex having PUFA-PKS activity and the proteins constituting the protein complex may be physically bound to each other or separated from each other as long as the protein complex has PUFA-PKS activity. Is also good.
- the protein constituting the protein complex having PUFA-PKS activity may be any of a wild-type protein, a homologous protein and a mutant protein as long as it is a protein having PUFA-PKS activity in cooperation with other proteins. .
- FIG. 1 shows proteins constituting PUFA-PKS derived from various microorganisms and their domain structures.
- Table 2 shows examples of amino acid sequences and base sequences of proteins constituting PUFA-PKS in various microorganisms.
- the nucleotide sequence encoding a protein constituting a protein complex having PUFA-PKS activity is not particularly limited as long as it is a nucleotide sequence encoding a protein having PUFA-PKS activity in cooperation with another protein.
- a 3-hydroxyhexanoyl in which the protein complex has the PUFA-PKS activity and the PS-DH domain is higher than the FabA-DH domain It is not particularly limited as long as it shows activity against ACP, and examples thereof include the following combinations.
- the amino acid sequence of each protein is as shown in Table 2.
- the microorganism (1) uses a microorganism having a PUFA metabolic pathway as a host organism, and has a higher activity against 3-hydroxyhexanoyl ACP than an endogenous FabA-DH domain, or a gene encoding an exogenous PS-DH domain or the PS-DH domain. It can be obtained by introducing and transfecting a gene encoding a protein having a DH domain.
- the microorganism (2) is prepared by introducing a gene encoding a domain having PUFA-PKS activity or a gene encoding a protein constituting PUFA-PKS, using a microorganism having no PUFA metabolic pathway as a host organism, Of the PS-DH domain among the domains having PUFA-PKS activity that is expressed in the host organism by the introduction of, the PS-DH domain is a domain showing higher activity against 3-hydroxyhexanoyl ACP than the FabA-DH domain.
- the gene encoding the PS-DH domain may be introduced into the host cell as a plasmid capable of autonomous replication, when the gene to be replaced in the host cell is replaced with a corresponding foreign gene, when the foreign PS gene is introduced. -Includes the case where the gene encoding the DH domain is incorporated into a region different from the gene encoding PUFA-PKS in the chromosomal DNA in the host cell.
- each domain constituting PUFA-PKS or the gene encoding the protein constituting PUFA-PKS may be introduced alone or in combination of two or more. It is only necessary to obtain a microorganism having a PS-DH domain that expresses a protein complex having PUFA-PKS activity and exhibits a higher activity for 3-hydroxyhexanoyl @ ACP than the FabA-DH domain.
- the term “gene” refers to a DNA that may contain a transcription control region, a promoter region, a terminator region, and the like in addition to a protein coding region.
- the DNA should be a suitable distance (eg, 6 to 18 bases) between the Shine-Dalgarno sequence, which is a ribosome binding region, and the initiation codon. It is preferable to use a plasmid adjusted to the above.
- a transcription termination factor is not always necessary for expression of the DNA, but it is preferable to arrange a transcription termination sequence immediately below the structural gene.
- the gene to be introduced into the host organism can be introduced into the host cell by, for example, using a recombinant gene inserted downstream of the promoter of an appropriate expression vector.
- the expression vector includes a promoter, a transcription termination signal, a selection marker gene for selecting a transformant (for example, kanamycin resistance gene, streptomycin resistance gene, carboxin resistance gene, zeocin resistance gene, drug resistance such as hygromycin resistance gene, etc.).
- Gene which complements an amino acid-required mutation such as leucine, histidine, methionine, arginine, tryptophan, lysine, etc., and a gene which complements a nucleobase-required mutation such as uracil, adenine, etc.).
- an orotidine-5'-phosphate decarboxylase gene ura3 gene
- an orotidylate pyrophosphorylase gene ura5 gene
- a promoter is defined as a DNA base sequence that initiates RNA synthesis by binding RNA polymerase to DNA, regardless of whether it is a constitutive promoter or a regulated promoter.
- a strong promoter is a promoter that initiates mRNA synthesis at a high frequency and is preferably used.
- lac system, trp system, TAC or TRC system, major operator and promoter regions of ⁇ phage, control region of fd coat protein, glycolytic enzymes (eg, 3-phosphoglycerate kinase, glyceraldehyde-3-phosphate dehydration) Promoters, glutamate decarboxylase A, and serine hydroxymethyltransferase can be used depending on the properties of the host cell.
- regulatory elements include, for example, selectable markers, amplification signals, origins of replication, and the like.
- Preferred regulatory sequences include, for example, the sequences described in “Gene Expression Technology: Methods in Enzymology 185” and Academic Press (1990).
- the vector there is no particular limitation on the vector as long as the gene of interest can be expressed. No particular limitation is imposed on the type of reagents for constructing the vector, for example, restriction enzymes or ligation enzymes, and commercially available products can be used as appropriate.
- the promoter in the case of using a Labyrinthura microorganism as a host organism is not particularly limited as long as it is a promoter that functions in the cells of the Labyrinthura microorganism, and examples thereof include an actin promoter, a tubulin promoter, an Elongation factor Tu promoter, and a promoter.
- An example is a sugar gene expression promoter.
- pColdI manufactured by Takara Bio Inc.
- pET21a pCOLADuet-1
- pACYCDuet-1 pCDF-1b
- pRSF-1b manufactured by Novagen
- pGEL1 Proc. Natl. Acad. Sci. USA, 82, 4306 (1985)]
- pBluescript II SK (+), pBluescript II KS (-) manufactured by Stratagene
- pTrS30 Escherichia coli JM109 / pTrS30 (adjusted from Ferm BP-5407), pTrS32] ⁇ Adjusted from Colli JM109 / pTrS32 (Ferm BP-5408)]
- pTK31 [APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2007, Vol. 73, no.
- pPAC31 (WO 98/12343), pUC19 [Gene, 33, 103 (1985)], pSTV28 (Takara Bio Inc.), pUC118 (Takara Bio Inc.), pPA1 (Japan JP-A-63-233798), pHSG298 (manufactured by Takara Bio Inc.), and pUC18 (manufactured by Takara Bio Inc.).
- the promoter is not particularly limited as long as it is a promoter that functions in cells of a microorganism belonging to the genus Escherichia.
- a trp promoter Ptrp
- lac lac promoter
- PL PL promoter
- PR promoter PR promoter
- promoters derived from Escherichia coli, phage, etc. such as PSE promoter, T7 promoter and the like.
- artificially designed and modified promoters such as a promoter in which two Ptrps are connected in series, a tac promoter, a trc promoter, a lacT7 promoter, and a letI promoter can also be used.
- examples of expression vectors include pCG1 (Japanese Patent Application Laid-Open No. 57-134500), pCG2 (Japanese Patent Application Laid-Open No. 58-35197), and pCG4 (Japanese Patent Application Laid-Open No. 58-35197). JP-A-57-183799), pCG11 (JP-A-57-134500), pCG116, pCE54, and pCB101 (all of which are JP-A-58-105999), pCE51, pCE52, and pCE53 [any of them] Molecular and General, Genetics, 196, 175 (1984)].
- the promoter is not particularly limited as long as it functions in a coryneform bacterium cell.
- a P54-6 promoter Appl. Microbiol. Biotechnol. , 53, 674-679 (2000).
- examples of expression vectors include YEp13 (ATCC37115), YEp24 (ATCC37051), YCp51 (ATCC37419), pHS19, and pHS15.
- the promoter in the case of using the expression vector is not particularly limited as long as it is a promoter that functions in cells of a yeast strain.
- a PH05 promoter, a PGK promoter, a GAP promoter, an ADH promoter, a gal @ 1 promoter, a gal @ 10 promoter, Promoters such as a heat shock polypeptide promoter, an MF ⁇ 1 promoter, and a CUP1 promoter are exemplified.
- a homologous recombination method As a method for integrating the gene to be introduced into the chromosome of the host organism, a homologous recombination method can be used.
- the homologous recombination method include a method of introducing a recombinant gene using a homologous recombination system that can be produced by ligating a plasmid DNA having a drug resistance gene that cannot be autonomously replicated in a parent strain to be introduced. it can.
- a method using homologous recombination frequently used in Escherichia coli a method of introducing a recombinant gene using a homologous recombination system of lambda phage [Proc. Natl. Acad. Sci. USA, 97, 6641-6645 (2000)].
- a selection method utilizing the fact that Escherichia coli becomes sucrose-sensitive by the Bacillus subtilis levan sucrose integrated on the chromosome together with the gene to be introduced, and a method of transferring a wild-type rpsL gene into Escherichia coli having a streptomycin-resistant mutant rpsL gene
- a selection method utilizing the fact that E. coli becomes streptomycin sensitive by integration [Mol. Microbiol. , 55, 137 (2005); Biosci. Biotechnol. Biochem. , 71, 905 (2007)] can be used to obtain a microorganism in which the target region on the chromosomal DNA of the parent strain has been replaced with the recombinant DNA.
- the present invention includes, but is not limited to, an improved method of the ATMT method.
- a method for introducing a gene to be introduced as a plasmid autonomously replicable in a host organism for example, a method using calcium ions [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972)], the protoplast method (Japanese Patent Application Laid-Open No. 63-248394), and the electroporation method [Nucleic Acids Res. , 16, 6127 (1988)].
- the fact that the microorganism obtained by the above method is the target microorganism means that the microorganism is cultured, PUFA accumulated in the culture is detected by gas chromatography, and the PS-DH domain is converted to FabA-DH by the above method. It can be confirmed by evaluating whether or not it shows activity against 3-hydroxyhexanoyl @ ACP higher than that of the domain.
- the present invention is characterized in that the microorganism thus formed is cultured in a medium, a PUFA or a PUFA-containing composition is produced and accumulated in the culture, and the PUFA or the PUFA-containing composition is collected from the culture. Includes methods for producing PUFAs or PUFA-containing compositions.
- PUFA or PUFA contained in the PUFA-containing composition is preferably ⁇ 6 PUFA, for example, DPA or ARA.
- the PUFA-containing composition includes, for example, PUFA-containing fats and oils or PUFA-containing phospholipids, preferably PUFA-containing fats and oils.
- a culture of the microorganism can be obtained by inoculating the microorganism into an appropriate medium and culturing the culture according to a conventional method.
- any known medium containing a carbon source, a nitrogen source, an inorganic salt and the like can be used.
- the carbon source include carbohydrates such as glucose, fructose, and galactose, oils and fats such as oleic acid and soybean oil, glycerol, and sodium acetate. These carbon sources can be used, for example, at a concentration of 20 to 300 g per liter of medium.
- the culture can be continued by feeding the carbon source. By culturing under such conditions, the amount of carbon source to be consumed can be increased, and the production of the PUFA-containing composition can be improved.
- the nitrogen source examples include organic nitrogen such as yeast extract, corn steep liquor, polypeptone, sodium glutamate, and urea, and inorganic nitrogen such as ammonium acetate, ammonium sulfate, ammonium chloride, sodium nitrate, ammonium nitrate, and ammonia.
- organic nitrogen such as yeast extract, corn steep liquor, polypeptone, sodium glutamate, and urea
- inorganic nitrogen such as ammonium acetate, ammonium sulfate, ammonium chloride, sodium nitrate, ammonium nitrate, and ammonia.
- potassium phosphate or the like can be appropriately used in combination.
- the medium containing each of the above components is preferably used after adjusting the pH to a range of 4.0 to 9.5 by adding an appropriate acid or base, followed by sterilization by an autoclave.
- the culture temperature is generally from 10 to 45 ° C, preferably from 20 to 37 ° C.
- the culture temperature is preferably controlled to a culture temperature at which a PUFA-containing composition can be produced.
- the pH at the time of culturing is generally 3.5 to 9.5, preferably 4.5 to 9.5.
- the particularly preferred pH varies depending on the purpose, and is from 5.0 to 8.0 in order to produce a large amount of fats and oils.
- the culturing time can be, for example, 2 to 7 days, and the culturing can be performed by aeration and stirring cultivation.
- the method of separating the culture solution and the microorganism from the culture can be performed by a conventional method known to those skilled in the art, for example, by centrifugation or filtration. After crushing the microorganisms separated from the above culture using, for example, ultrasonic waves or a dyno mill, the PUFA-containing composition can be obtained by performing solvent extraction with, for example, chloroform, hexane, or butanol.
- the PUFA-containing composition produced by the above-mentioned production method may be, for example, a low-temperature solvent fractionation method [Shotataro Takahashi, Oil Chemistry, 40: 931-941 (1991)], or a short-chain fatty acid with a hydrolase such as lipase.
- a PUFA-containing composition having a high PUFA content can be obtained by concentrating a PUFA-containing composition by a method such as a method of removing elimination [Kotaro Takahashi, Yuyu Kagaku, 40: 931-941 (1991)] or the like.
- PU PUFA can be produced by separating and collecting PUFA from the PUFA-containing composition. For example, after preparing a mixed fatty acid containing PUFA from a PUFA-containing composition by a hydrolysis method, for example, the PUFA is separated by a urea addition method, a cooling separation method, a high performance liquid chromatography method, a supercritical chromatography method, or the like. PUFA can be produced by collecting the urea.
- PUFA alkyl esters can be produced by separating and collecting PUFA alkyl esters from the PUFA-containing composition.
- the PUFA alkyl ester is not particularly limited as long as it is a PUFA alkyl ester, and is preferably a PUFA ethyl ester.
- a mixed fatty acid alkyl ester containing a PUFA alkyl ester is prepared from the PUFA-containing composition by an alcoholysis method, and then, for example, a urea addition method, cooling separation
- the method can be carried out by separating and collecting the PUFA alkyl ester by a method, high performance liquid chromatography or supercritical chromatography.
- ARA manufacturing method-1 Construction of each expression plasmid [construction of pET-phoA] PCR was performed using the genomic DNA of Photobacterium profundum SS99 (ATCC BAA-1252) strain extracted by a conventional method as a template using the primers represented by SEQ ID NOS: 107 and 108, and the DNA encoding the PhoA protein (represented by SEQ ID NO: 65). The 3 ′ end region (from the 633rd base to the stop codon) was amplified.
- the obtained DNA fragment was treated with restriction enzymes BamHI and EagI, and ligated with the same restriction enzyme-treated Escherichia coli vector pBluescript ⁇ II ⁇ SK (+) (manufactured by Agilent Technologies) to obtain pBlue-PhoA-C-. Terminal was obtained.
- PCR was carried out using the genomic DNA of Photobacterium ⁇ profundum ⁇ SS99 strain extracted by a conventional method as a template and the primers represented by SEQ ID NOS: 109 and 110, and the 5 'end region of the DNA encoding the PhoA protein (from the start codon to the Up to the 633rd base).
- the obtained DNA fragment and Escherichia coli vector pET21a (manufactured by Merck Millipore) were treated with restriction enzymes NdeI and EagI, respectively, and the obtained restriction enzyme-treated fragments were ligated to obtain pET-phoA-N-terminal.
- pBlue-PhoA-C-terminal and pET-phoA-N-terminal were treated with restriction enzymes EagI and XhoI, respectively, and the obtained restriction enzyme-treated fragments were ligated to obtain pET-phoA.
- PCR was performed using the genomic DNA of Photobacterium profundum SS99 strain extracted by a conventional method as a template and the primers represented by SEQ ID NOS: 111 and 112, and the DNA encoding the PhoD protein (DNA consisting of the nucleotide sequence represented by SEQ ID NO: 71) ) was amplified.
- the obtained DNA fragment was treated with restriction enzymes NdeI and BamHI, and ligated with E. coli vector pCOLADuet-1 (manufactured by Merck Millipore) which had been treated with NdeI and BglII to obtain pCOLA-phoD.
- PCR was carried out using the genomic DNA of Photobacterium ⁇ profundum ⁇ SS99 strain extracted by a conventional method as a template using the primers represented by SEQ ID NOS: 113 and 114, and the DNA encoding the PhoB protein (a DNA comprising the base sequence represented by SEQ ID NO: 67) ) was amplified.
- the obtained DNA fragment was treated with restriction enzymes NdeI and BamHI, and ligated with pACYC-SoppaE which had been treated with NdeI and BglII to obtain pACYC-epaE-phoB.
- PCR PCR was performed using pACYC-epaE-phoB as a template and primers represented by SEQ ID NOS: 114 and 115 to obtain a DNA fragment having a DNA encoding the PhoB protein.
- PCR was carried out using the E. coli vector pCOLADuet-1 (manufactured by Merck Millipore) as a template and primers represented by SEQ ID NOS: 116 and 117 to amplify a DNA fragment of the T7 promoter region.
- the obtained two DNA fragments were assembled by overlap extension PCR.
- the obtained DNA fragment and pCOLA-phoD were treated with restriction enzymes ApaI and BamHI, respectively, and the obtained restriction enzyme-treated fragment was ligated to obtain pCOLA-phoD-phoB.
- [Construction of pCDF-phoC] PCR was performed using the genomic DNA of Photobacterium profundum SS99 strain extracted by a conventional method as a template using the primers represented by SEQ ID NOS: 118 and 119, and a DNA encoding the PhoC protein (a DNA comprising the base sequence represented by SEQ ID NO: 69) ) was amplified from the start codon to the 993th base.
- PCR was carried out using the genomic DNA of Photobacterium ro profundum SS99 strain extracted by a conventional method as a template and the primers represented by SEQ ID NOS: 120 and 121, and the 3'-terminal region of the DNA encoding the PhoC protein (933rd From the base to the stop codon).
- the obtained DNA fragment and pCDF-phoC-N-terminal were treated with restriction enzymes NcoI and BamHI, and the obtained restriction enzyme-treated fragment was ligated to obtain pCDF-phoC.
- PCR was performed using the genomic DNA of Shewanella oneidensis MR-1 (ATCC BAA-1096) strain extracted by a conventional method as a template and primers represented by SEQ ID NOS: 122 and 123, and a DNA encoding the EpaA protein (SEQ ID NO: 73) A DNA fragment having a base sequence represented by the following formula: was amplified.
- the obtained DNA fragment and Escherichia coli vector pET21a (manufactured by Merck Millipore) were treated with restriction enzymes EcoRI and XhoI, and the obtained restriction enzyme-treated fragment was ligated to obtain pET-epaA ′.
- overlap extension PCR was performed using pET-epaA 'as a template and primers represented by SEQ ID NOS: 124, 125, 126 and 127 to amplify the EpaA gene excluding the 5'-terminal His-tag gene. .
- the obtained DNA fragment and pET-epaA ' were treated with restriction enzymes ApaI and SalI, and the obtained restriction enzyme-treated fragment was ligated to obtain pET-epaA.
- the obtained DNA fragment and Escherichia coli vector pET21a (manufactured by Merck Millipore) were treated with restriction enzymes NdeI and BamHI, and the obtained restriction enzyme-treated fragment was ligated to obtain pET-araA.
- PCR was performed using pSTV29-Plac-pfaAB (FEBS Lett., 2014, 588 (21), 4032-4036) as a template and primers represented by SEQ ID NOS: 130 and 131, and DNA encoding AraB protein (SEQ ID NO: A DNA fragment having a base sequence represented by SEQ ID NO: 57) was amplified.
- the obtained DNA fragment was treated with restriction enzymes NdeI and BamHI, and ligated with pACYC-SoppaE treated with NdeI and BglII to obtain pACYC-epaE-araB.
- the obtained DNA fragment and pCDF-orfB (Sci. Rep., 2016, 6, 35441) were treated with restriction enzymes NdeI and BamHI, and the obtained restriction enzyme-treated fragment was ligated to obtain pCDF-araC. .
- the obtained DNA fragment was treated with restriction enzymes NdeI and BamHI, and ligated with E. coli vector pCOLADuet-1 (manufactured by Merck Millipore) treated with NdeI and BglII to obtain pCOLA-araD.
- the obtained Escherichia coli was inoculated into 2 mL of a Terrific Broth medium (manufactured by Becton, Dickinson and Company) containing 100 mg / L of ampicillin, 20 mg / L of kanamycin, 30 mg / L of chloramphenicol, and 20 mg / L of streptomycin. Shaking culture was performed at 16 ° C. for 16 hours.
- 1 mL of the obtained culture solution was newly prepared in a Terrific Broth medium (Becton Dickinson & Company) containing 100 mg / L ampicillin, 20 mg / L kanamycin, 30 mg / L chloramphenicol, 20 mg / L streptomycin, and 1 mM IPTG. (Manufactured by Ajinomoto Co., Inc.) into a 200 mL-winged flask containing 20 mL, and cultured at 230 rpm at 20 ° C. for 48 hours.
- a Terrific Broth medium Becton Dickinson & Company
- a culture solution is collected and subjected to the Blight-Dyer method [Bright, e. G. FIG. and @Dyer, W.C. J. (1959) Can. J. Biochem. Physiol. 37, 911-917], the fatty acid was methylated with a boron trifluoride / methanol solution, and analyzed by gas chromatography-mass spectrometry.
- Table 3 shows the results of measurement of ARA, EPA, dihomo- ⁇ -linolenic acid (hereinafter referred to as DGLA) and eicosatetraenoic acid (hereinafter referred to as ETA) in the culture solution.
- DGLA dihomo- ⁇ -linolenic acid
- ETA eicosatetraenoic acid
- Escherichia coli producing PhoA protein, PhoB protein, PhoC protein, PhoD protein and EpaE protein mainly produced EPA and did not produce ARA, whereas PhoA protein, PhoB protein, PhoC protein, Escherichia coli, which also produces AraB protein in addition to PhoD and EpaE proteins, produced ARA in the same amount as EPA.
- the obtained Escherichia coli was inoculated into 2 mL of a Terrific Broth medium (manufactured by Becton, Dickinson and Company) containing 100 mg / L of ampicillin, 20 mg / L of kanamycin, 30 mg / L of chloramphenicol, and 20 mg / L of streptomycin. Shaking culture was performed at 16 ° C. for 16 hours.
- 1 mL of the obtained culture solution was newly prepared in a Terrific Broth medium (Becton Dickinson & Company) containing 100 mg / L ampicillin, 20 mg / L kanamycin, 30 mg / L chloramphenicol, 20 mg / L streptomycin, and 1 mM IPTG. (Manufactured by K.K.) in a 200-mL winged flask containing 20 mL, and cultured at 230 rpm and 20 ° C. for 48 hours.
- a Terrific Broth medium Becton Dickinson & Company
- Table 4 shows the results of measuring ARA, EPA, DGLA and ETA in the culture solution.
- EpaA protein, PhoB protein, PhoC protein, Escherichia coli producing PhoD protein and EpaE protein mainly produced EPA and did not produce ARA
- the obtained Escherichia coli was inoculated into 2 mL of a Terrific Broth medium (manufactured by Becton, Dickinson and Company) containing 100 mg / L of ampicillin, 20 mg / L of kanamycin, 30 mg / L of chloramphenicol, and 20 mg / L of streptomycin. Shaking culture was performed at 16 ° C. for 16 hours.
- 1 mL of the obtained culture solution was newly prepared in a Terrific Broth medium (Becton Dickinson & Company) containing 100 mg / L ampicillin, 20 mg / L kanamycin, 30 mg / L chloramphenicol, 20 mg / L streptomycin, and 1 mM IPTG. (Manufactured by Ajinomoto Co., Inc.) into a 200 mL-winged flask containing 20 mL, and cultured at 230 rpm at 20 ° C. for 48 hours.
- a Terrific Broth medium Becton Dickinson & Company
- Table 5 shows the results of measuring ARA, EPA, DGLA and ETA in the culture solution.
- Escherichia coli producing AraA protein, AraB protein, AraC protein, AraD protein and EpaE protein had all PUFAs below the detection limit, whereas EpaA protein, AraB protein, AraC protein and AraD protein.
- E. coli producing E. coli and EpaE proteins and E. coli producing PhoA, AraB, AraC, AraD and EpaE proteins produced significant amounts of ARA.
- Example 2 Manufacturing method of DPA Construction of each expression plasmid [pET-orfA] According to a method similar to that of Hayashi et al. (Sci. Rep., 2016, 6, 35441), Shizochytrium sp. An expression plasmid pET-orfA having DNA encoding the OrfA protein (DNA having the nucleotide sequence represented by SEQ ID NO: 83) derived from the (ATCC20888) strain was obtained.
- PCDF-orfB According to a method similar to that of Hayashi et al. (Sci. Rep., 2016, 6, 35441), Shizochytrium sp.
- the obtained Escherichia coli was inoculated into 2 mL of a Terrific Broth medium (manufactured by Becton, Dickinson and Company) containing 100 mg / L of ampicillin, 20 mg / L of kanamycin, 30 mg / L of chloramphenicol, and 20 mg / L of streptomycin. Shaking culture was performed at 16 ° C. for 16 hours.
- 1 mL of the obtained culture solution was newly prepared in a Terrific Broth medium (Becton Dickinson & Company) containing 100 mg / L ampicillin, 20 mg / L kanamycin, 30 mg / L chloramphenicol, 20 mg / L streptomycin, and 1 mM IPTG. (Manufactured by K.K.) in a 200-mL winged flask containing 20 mL, and cultured at 230 rpm and 20 ° C. for 48 hours.
- a Terrific Broth medium Becton Dickinson & Company
- Table 6 shows the results of measuring DPA, DHA, EPA and ETA in the culture solution.
- Escherichia coli producing OrfA protein, OrfB protein, OrfC protein and EpaE protein mainly produced DHA
- E. coli producing AraB protein in addition to OrfA protein, OrfB protein, OrfC protein and EpaE protein E. coli produced DPA equal to or greater than DHA.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
2.PUFA代謝経路を有する微生物がω3PUFA代謝経路を有する微生物であり、生産し得るPUFAがω6PUFAである、前記1に記載の微生物。
3.PUFA代謝経路を有する微生物がEPA又はDHA代謝経路を有する微生物であり、生産し得るPUFAがARA又はDPAである、前記1又は2に記載の微生物。
4.PUFA代謝経路を有する微生物がシュワネラ(Shewanella)属、フォトバクテリウム(Photobacterium)属、モリテラ(Moritella)属、コルウェリア(Colwellia)属、オーランチオキトリウム(Aurantiochytrium)属、スラウストキトリウム(Thraustochytrium)属、ウルケニア(Ulkenia)属、パリエチキトリウム(Parietichytrium)属、ラビリンチュラ(Labyrinthula)属、アプラノキトリウム(Aplanochytrium)属、オブロンギキトリウム(Oblongichytrium)属、又はシゾキトリウム(Schizochytrium)属に由来する前記1~3のいずれか1に記載の微生物。
5.PUFA代謝経路を有さない微生物に、PUFA-PKS活性を有する下記(a)~(j)に記載の各ドメインをコードする遺伝子が導入された、PUFAを生産し得る微生物であって、PS-DHドメインがFabA-DHドメインよりも高い3-hydroxyhexanoyl ACPに対する活性を示す微生物。
(a)KSドメイン
(b)MATドメイン
(c)ACPドメイン
(d)KRドメイン
(e)PS-DHドメイン
(f)CLFドメイン
(g)ATドメイン
(h)FabA-DHドメイン
(i)ERドメイン
(j)PPTドメイン
6.前記1~4のいずれか1に記載のPUFAを生産し得る微生物が有するPUFA合成系遺伝子を全て有する前記5に記載の微生物。
7.生産し得るPUFAがω6PUFAである前記5又は6に記載の微生物。
8.生産し得るPUFAがARA又はDPAである前記5~7のいずれか1に記載の微生物。
9.PUFA代謝経路を有さない微生物がエシェリヒア(Escherichia)属、バチルス(Bacillus)属、コリネバクテリウム(Corynebacterium)属、ヤロウィア(Yarrowia)属、サッカロマイセス(Saccharomyces)属、カンジダ(Candida)属、又はピキア(Pichia)属に属する微生物である前記5~8のいずれか1に記載の微生物。
10.PS-DHドメインが、Aureispira marina由来のAraBのPS-DHドメインである、前記1~9のいずれか1に記載の微生物。
11.前記1~10のいずれか1に記載の微生物を培地に培養し、培養物中にPUFA又はPUFA含有組成物を生成、蓄積させ、該培養物からPUFA又はPUFA含有組成物を採取する、PUFA又はPUFA含有組成物の製造法。
12.下記(I)又は(II)のPUFAを生産し得る微生物を用いるPUFA又はPUFA含有組成物の製造法。
(I)PUFA代謝経路を有する微生物に、3-hydroxyhexanoyl ACPに対する活性が内在のFabA-DHドメインよりも高いPS-DHドメインをコードする遺伝子が導入された、PUFAを生産し得る微生物。
(II)PUFA代謝経路を有さない微生物に、PUFA-PKS活性を有する下記(a)~(j)に記載の各ドメインをコードする遺伝子が導入された、PUFAを生産し得る微生物であって、PS-DHドメインがFabA-DHドメインよりも高い3-hydroxyhexanoyl ACPに対する活性を示す微生物。
(a)KSドメイン
(b)MATドメイン
(c)ACPドメイン
(d)KRドメイン
(e)PS-DHドメイン
(f)CLFドメイン
(g)ATドメイン
(h)FabA-DHドメイン
(i)ERドメイン
(j)PPTドメイン
本発明の微生物としては、下記(1)又は(2)の微生物が挙げられる。
(1)PUFA代謝経路を有する微生物に、3-hydroxyhexanoyl ACPに対する活性が、FabA-DHドメインよりも高い、外来のPS-DHドメインをコードする遺伝子が導入された、PUFAを生産し得る微生物。
(2)PUFA代謝経路を有さない微生物に、PUFA-PKS活性を有するKS、MAT、ACP、KR、PS-DH、CLF、AT、FabA-DH、ER、PPTaseの各ドメインをコードする遺伝子が導入された、PUFAを生産し得る微生物であって、PS-DHドメインがFabA-DHドメインよりも高い3-hydroxyhexanoyl ACPに対する活性を示す微生物。
Tris-HCl 80mM、NaCl 80mM、MgCl2 25mM、基質となるACP 100μM、Sfp 20μM、アシル-CoA 300μMを混合し、20℃にて10分間反応させた系に、PS-DHドメイン及びFabA-DHドメインを含む蛋白質を1μMまたは5μM添加して、20℃にて反応させる。反応開始から1、5、10、30、60分後にサンプルを回収し、LC/MS分析を行い、HPLCピークの高さを解析する。前記Sfpとは、バチルス・サブチリス(Bacillus subtilis)由来の4’-phosphopantetheinyl transferaseを意味する。
[1]配列番号2又は配列番号137で表されるアミノ酸配列を有する蛋白質
[2]配列番号2又は配列番号137で表されるアミノ酸配列において、1~20個、好ましくは1~10個、最も好ましくは1~5個のアミノ酸が欠失、置換又は付加されたアミノ酸配列からなり、かつ、3-hydroxyhexanoyl ACPに対する活性を有する変異蛋白質
[3]配列番号2又は配列番号137で表されるアミノ酸配列と少なくとも95%以上、好ましくは97%以上、より好ましくは98%以上、最も好ましくは99%以上の同一性を有し、かつ、3-hydroxyhexanoyl ACPに対する活性を有する相同蛋白質
[4]配列番号58又は配列番号138で表されるアミノ酸配列を有する蛋白質
[5]配列番号58又は配列番号138で表されるアミノ酸配列において、1~20個、好ましくは1~10個、最も好ましくは1~5個のアミノ酸が欠失、置換又は付加されたアミノ酸配列からなり、かつ、3-hydroxyhexanoyl ACPに対する活性を有する変異蛋白質
[6]配列番号58又は配列番号138で表されるアミノ酸配列と少なくとも95%以上、好ましくは97%以上、より好ましくは98%以上、最も好ましくは99%以上の同一性を有し、かつ、3-hydroxyhexanoyl ACPに対する活性を有する相同蛋白質
A群:ロイシン、イソロイシン、ノルロイシン、バリン、ノルバリン、アラニン、2-アミノブタン酸、メチオニン、O-メチルセリン、t-ブチルグリシン、t-ブチルアラニン、シクロヘキシルアラニン
B群:アスパラギン酸、グルタミン酸、イソアスパラギン酸、イソグルタミン酸、2-アミノアジピン酸、2-アミノスベリン酸
C群:アスパラギン、グルタミン
D群:リジン、アルギニン、オルニチン、2,4-ジアミノブタン酸、2,3-ジアミノプロピオン酸
E群:プロリン、3-ヒドロキシプロリン、4-ヒドロキシプロリン
F群:セリン、スレオニン、ホモセリン
G群:フェニルアラニン、チロシン
[7]上記[1]~[3]のいずれか1の蛋白質をコードするDNA
[8]配列番号136又は配列番号139で表される塩基配列を含むDNA
[9]前記[7]又は[8]に記載のDNAと相補的な塩基配列からなるDNAとストリンジェントな条件でハイブリダイズし、かつ、3-hydroxyhexanoyl ACPに対する活性を有する相同蛋白質をコードするDNA
[10]前記[7]又は[8]に記載のDNAの塩基配列と少なくとも95%以上、好ましくは97%以上、より好ましくは98%以上、最も好ましくは99%以上の同一性を有し、かつ、3-hydroxyhexanoyl ACPに対する活性を有する相同蛋白質をコードするDNA
[11]上記[4]~[6]のいずれか1の蛋白質をコードするDNA
[12]配列番号57又は配列番号140で表される塩基配列を含むDNA
[13]前記[11]又は[12]に記載のDNAの塩基配列と相補的な塩基配列からなるDNAとストリンジェントな条件でハイブリダイズし、かつ、3-hydroxyhexanoyl ACPに対する活性を有する相同蛋白質をコードするDNA
[14]前記[11]又は[12]記載のDNAの塩基配列と少なくとも95%以上、好ましくは97%以上、より好ましくは98%以上、最も好ましくは99%以上の同一性を有し、かつ、3-hydroxyhexanoyl ACPに対する活性を有する相同蛋白質をコードするDNA
(i)PhoA、PhoB、PhoC、PhoD、EpaE、AraB
(ii)EpaA、PhoB、PhoC、PhoD、EpaE、AraB
(iii)EpaA、AraB、AraC、AraD、EpaE
(iv)PhoA、AraB、AraC、AraD、EpaE
微生物(1)は、PUFA代謝経路を有する微生物を宿主生物として、3-hydroxyhexanoyl ACPに対する活性が、内在のFabA-DHドメインよりも高い、外来のPS-DHドメインをコードする遺伝子、又は該PS-DHドメインを有する蛋白質をコードする遺伝子を導入して形質転換することにより得られる。
本発明は、上記造成された微生物を培地に培養し、培養物中にPUFA又はPUFA含有組成物を生成、蓄積させ、該培養物からPUFA又はPUFA含有組成物を採取することを特徴とする、PUFA又はPUFA含有組成物の製造法を含む。
ARAの製造法-1
1.各発現プラスミドの造成
[pET-phoAの造成]
常法により抽出したPhotobacterium profundum SS99(ATCC BAA-1252)株のゲノムDNAを鋳型に、配列番号107及び108で表わされるプライマーを用いてPCRを行い、PhoA蛋白質をコードするDNA(配列番号65で表わされる塩基配列からなるDNA)の3’末端領域(633番目の塩基から停止コドンまで)を増幅した。
林ら(Sci.Rep.,2016,6,35441)と同様の方法により、Shewanella oneidensis MR-1(ATCC BAA-1096)株由来のEpaE蛋白質をコードするDNA(配列番号81で表わされる塩基配列からなるDNA)を有する発現プラスミドpACYC-SopfaEを得た。
常法により抽出したPhotobacterium profundum SS99株のゲノムDNAを鋳型に、配列番号111及び112で表わされるプライマーを用いてPCRを行い、PhoD蛋白質をコードするDNA(配列番号71で表わされる塩基配列からなるDNA)を有するDNA断片を増幅した。
常法により抽出したPhotobacterium profundum SS99株のゲノムDNAを鋳型に、配列番号118及び119で表わされるプライマーを用いてPCRを行い、PhoC蛋白質をコードするDNA(配列番号69で表わされる塩基配列からなるDNA)の5’末端領域(開始コドンから993番目の塩基まで)を増幅した。
常法により抽出したShewanella oneidensis MR-1(ATCC BAA-1096)株のゲノムDNAを鋳型に、配列番号122及び123で表わされるプライマーを用いてPCRを行い、EpaA蛋白質をコードするDNA(配列番号73で表わされる塩基配列からなるDNA)を有するDNA断片を増幅した。
pSTV29-Plac-pfaAB[FEBS Lett.,2014,588(21),4032-4036]を鋳型に、配列番号128及び129で表わされるプライマーを用いてPCRを行い、AraA蛋白質をコードするDNA(配列番号55で表わされる塩基配列からなるDNA)を有するDNA断片を増幅した。
pSTV29-Plac-pfaAB(FEBS Lett.,2014,588(21),4032-4036)を鋳型に、配列番号130及び131で表わされるプライマーを用いてPCRを行い、AraB蛋白質をコードするDNA(配列番号57で表わされる塩基配列からなるDNA)を有するDNA断片を増幅した。
pMW219-Plac-pfaCD[FEBS Lett.,2014,588(21),4032-4036]を鋳型に、配列番号132及び133で表わされるプライマーを用いてPCRを行い、AraC蛋白質をコードするDNA(配列番号59で表わされる塩基配列からなるDNA)を有するDNA断片を増幅した。
pMW219-Plac-pfaCD[FEBS Lett.,2014,588(21),4032-4036]を鋳型に、配列番号134及び135で表わされるプライマーを用いてPCRを行い、AraD蛋白質をコードするDNA(配列番号61で表わされる塩基配列からなるDNA)を有するDNA断片を増幅した。
林ら(Sci.Rep.,2016,6,35441)と同様の方法で、アシル-CoAデヒドロゲナーゼFadE(配列番号106で表わされるアミノ酸配列からなる蛋白質)をコードする遺伝子が欠失した大腸菌BLR(DE3)ΔfadE株を造成した。
〈3〉pET-epaA、pCDF-phoC、pCOLA-phoD-phoB及びpACYC-SopfaE、又は〈4〉pET-epaA、pCDF-phoC、pCOLA-phoD-phoB及びpACYC-epaE-araBで大腸菌BLR(DE3)ΔfadE株を形質転換した。
〈5〉pET-araA、pCDF-araC、pCOLA-araD及びpACYC-epaE-araB、〈6〉pET-epaA、pCDF-araC、pCOLA-araD及びpACYC-epaE-araB、又は〈7〉pET-phoA、pCDF-araC、pCOLA-araD及びpACYC-epaE-araBで大腸菌BLR(DE3)ΔfadE株を形質転換した。
DPAの製造法
1.各発現プラスミドの造成
[pET-orfA]
林ら(Sci.Rep.,2016,6,35441)と同様の方法により、Shizochytorium sp.(ATCC20888)株由来のOrfA蛋白質をコードするDNA(配列番号83で表わされる塩基配列からなるDNA)を有する発現プラスミドpET-orfAを得た。
林ら(Sci.Rep.,2016,6,35441)と同様の方法により、Shizochytorium sp.(ATCC20888)株由来のOrfB蛋白質をコードするDNA(配列番号85で表わされる塩基配列からなるDNA)を有する発現プラスミドpCDF-orfBを得た。
林ら(Sci.Rep.,2016,6,35441)と同様の方法により、Shizochytorium sp.(ATCC20888)株由来のOrfC蛋白質をコードするDNA(配列番号87で表わされる塩基配列からなるDNA)を有する発現プラスミドpET-orfAを得た。
〈8〉pET-orfA、pCDF-orfB、pCOL92及びpACYC-SopfaE、又は〈9〉pET-orfA、pCDF-orfB、pCOL92及びpACYC-epaE-araBで大腸菌BLR(DE3)ΔfadE株を形質転換した。
Claims (12)
- 多価不飽和脂肪酸(以下、PUFAという。)代謝経路を有する微生物に、3-ヒドロキシヘキサノイル アシルキャリアー蛋白質(以下、3-hydroxyhexanoyl ACPという。)に対する活性が、内在のFabA様β-ヒドロキシアシル-ACPデヒドラターゼ(以下、FabA-DHという。)ドメインよりも高い、外来のポリケチドシンターゼデヒドラターゼ(以下、PS-DHという。)ドメインをコードする遺伝子が導入された、PUFAを生産し得る微生物。
- PUFA代謝経路を有する微生物がω3PUFA代謝経路を有する微生物であり、生産し得るPUFAがω6PUFAである、請求項1に記載の微生物。
- PUFA代謝経路を有する微生物がエイコサペンタエン酸(以下、EPAという。)又はドコサヘキサエン酸(以下、DHAという。)代謝経路を有する微生物であり、生産し得るPUFAがアラキドン酸(以下、ARAという。)又はドコサペンタエン酸(以下、DPAという。)である、請求項1又は2に記載の微生物。
- PUFA代謝経路を有する微生物がシュワネラ(Shewanella)属、フォトバクテリウム(Photobacterium)属、モリテラ(Moritella)属、コルウェリア(Colwellia)属、オーランチオキトリウム(Aurantiochytrium)属、スラウストキトリウム(Thraustochytrium)属、ウルケニア(Ulkenia)属、パリエチキトリウム(Parietichytrium)属、ラビリンチュラ(Labyrinthula)属、アプラノキトリウム(Aplanochytrium)属、オブロンギキトリウム(Oblongichytrium)属、又はシゾキトリウム(Schizochytrium)属に由来する請求項1~3のいずれか1項に記載の微生物。
- PUFA代謝経路を有さない微生物に、PUFAを合成する活性(以下、PUFA-PKS活性という。)を有する下記(a)~(j)に記載の各ドメインをコードする遺伝子が導入された、PUFAを生産し得る微生物であって、PS-DHドメインがFabA-DHドメインよりも高い3-hydroxyhexanoyl ACPに対する活性を示す微生物。
(a)β-ケトアシル-ACPシンターゼ(以下、KSという。)ドメイン
(b)マロニル-CoA:ACPアシルトランスフェラーゼ(以下、MATという。)ドメイン
(c)ACPドメイン
(d)ケトレダクターゼ(以下、KRという。)ドメイン
(e)PS-DHドメイン
(f)鎖伸長因子(以下、CLFという。)ドメイン
(g)アシルトランスフェラーゼ(以下、ATという。)ドメイン
(h)FabA-DHドメイン
(i)エノイルACP-レダクターゼ(以下、ERという。)ドメイン
(j)ホスホパンテテイントランスフェラーゼ(以下、PPTという。)ドメイン - 請求項1~4のいずれか1項に記載のPUFAを生産し得る微生物が有するPUFA合成系遺伝子を全て有する請求項5に記載の微生物。
- 生産し得るPUFAがω6PUFAである請求項5又は6に記載の微生物。
- 生産し得るPUFAがARA又はDPAである請求項5~7のいずれか1項に記載の微生物。
- PUFA代謝経路を有さない微生物がエシェリヒア(Escherichia)属、バチルス(Bacillus)属、コリネバクテリウム(Corynebacterium)属、ヤロウィア(Yarrowia)属、サッカロマイセス(Saccharomyces)属、カンジダ(Candida)属、又はピキア(Pichia)属に属する微生物である請求項5~8のいずれか1項に記載の微生物。
- PS-DHドメインが、Aureispira marina由来のAraBのPS-DHドメインである、請求項1~9のいずれか1項に記載の微生物。
- 請求項1~10のいずれか1項に記載の微生物を培地に培養し、培養物中にPUFA又はPUFA含有組成物を生成、蓄積させ、該培養物からPUFA又はPUFA含有組成物を採取する、PUFA又はPUFA含有組成物の製造法。
- 下記(I)又は(II)のPUFAを生産し得る微生物を用いるPUFA又はPUFA含有組成物の製造法。
(I)PUFA代謝経路を有する微生物に、3-hydroxyhexanoyl ACPに対する活性が内在のFabA-DHドメインよりも高いPS-DHドメインをコードする遺伝子が導入された、PUFAを生産し得る微生物。
(II)PUFA代謝経路を有さない微生物に、PUFA-PKS活性を有する下記(a)~(j)に記載の各ドメインをコードする遺伝子が導入された、PUFAを生産し得る微生物であって、PS-DHドメインがFabA-DHドメインよりも高い3-hydroxyhexanoyl ACPに対する活性を示す微生物。
(a)KSドメイン
(b)MATドメイン
(c)ACPドメイン
(d)KRドメイン
(e)PS-DHドメイン
(f)CLFドメイン
(g)ATドメイン
(h)FabA-DHドメイン
(i)ERドメイン
(j)PPTドメイン
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201980053748.9A CN112567019A (zh) | 2018-08-10 | 2019-08-09 | 生产多不饱和脂肪酸的微生物和多不饱和脂肪酸的制造方法 |
EP19848558.3A EP3835412A4 (en) | 2018-08-10 | 2019-08-09 | POLYUNSATURATED FATTY ACID PRODUCING MICROORGANISM AND PROCESS FOR THE PRODUCTION OF POLYUNSATURATED FATTY ACID |
BR112021002299-6A BR112021002299A2 (pt) | 2018-08-10 | 2019-08-09 | micro-organismo produzindo ácido graxo poli-insaturado e método para produzir ácido graxo poli-insaturado |
US17/266,976 US20210309987A1 (en) | 2018-08-10 | 2019-08-09 | Microorganism producing polyunsaturated fatty acid and method for producing polyunsaturated fatty acid |
JP2020535919A JPWO2020032258A1 (ja) | 2018-08-10 | 2019-08-09 | 多価不飽和脂肪酸を生産する微生物及び多価不飽和脂肪酸の製造法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018151233 | 2018-08-10 | ||
JP2018-151233 | 2018-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020032258A1 true WO2020032258A1 (ja) | 2020-02-13 |
Family
ID=69414174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/031649 WO2020032258A1 (ja) | 2018-08-10 | 2019-08-09 | 多価不飽和脂肪酸を生産する微生物及び多価不飽和脂肪酸の製造法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210309987A1 (ja) |
EP (1) | EP3835412A4 (ja) |
JP (1) | JPWO2020032258A1 (ja) |
CN (1) | CN112567019A (ja) |
BR (1) | BR112021002299A2 (ja) |
WO (1) | WO2020032258A1 (ja) |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57134500A (en) | 1981-02-12 | 1982-08-19 | Kyowa Hakko Kogyo Co Ltd | Plasmid pcg1 |
JPS57183799A (en) | 1981-04-17 | 1982-11-12 | Kyowa Hakko Kogyo Co Ltd | Novel plasmid |
JPS5835197A (ja) | 1981-08-26 | 1983-03-01 | Kyowa Hakko Kogyo Co Ltd | プラスミドpcg2 |
JPS58105999A (ja) | 1981-12-17 | 1983-06-24 | Kyowa Hakko Kogyo Co Ltd | 新規ベクタ−プラスミド |
JPS58110600A (ja) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
JPS63233798A (ja) | 1986-10-09 | 1988-09-29 | Kyowa Hakko Kogyo Co Ltd | 5′−グアニル酸の製造法 |
JPS63248394A (ja) | 1987-04-06 | 1988-10-14 | Kyowa Hakko Kogyo Co Ltd | 核酸関連物質の製造法 |
WO1998012343A1 (fr) | 1996-09-17 | 1998-03-26 | Kyowa Hakko Kogyo Co., Ltd. | Procedes de production de nucleotides de sucre et de glucides complexes |
JP2006219528A (ja) | 2005-02-08 | 2006-08-24 | Suntory Ltd | 新規な菌体処理方法を用いた高度不飽和脂肪酸の製造方法 |
WO2008144473A2 (en) | 2007-05-16 | 2008-11-27 | Martek Biosciences Corporation | Chimeric pufa polyketide synthase systems and uses thereof |
JP2011516045A (ja) * | 2008-03-28 | 2011-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ポリケチドシンターゼを使用するジカルボン酸の生成法 |
WO2015025920A1 (ja) * | 2013-08-22 | 2015-02-26 | 協和発酵バイオ株式会社 | アラキドン酸生産ポリケチドシンターゼ及びその利用 |
JP2017184690A (ja) * | 2016-04-08 | 2017-10-12 | 協和発酵バイオ株式会社 | 多価不飽和脂肪酸ポリケチドシンターゼ及びその利用 |
JP2018151233A (ja) | 2017-03-13 | 2018-09-27 | 株式会社東芝 | 放射線測定装置 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566583B1 (en) * | 1997-06-04 | 2003-05-20 | Daniel Facciotti | Schizochytrium PKS genes |
US7217856B2 (en) * | 1999-01-14 | 2007-05-15 | Martek Biosciences Corporation | PUFA polyketide synthase systems and uses thereof |
US7211418B2 (en) * | 1999-01-14 | 2007-05-01 | Martek Biosciences Corporation | PUFA polyketide synthase systems and uses thereof |
TWI426127B (zh) * | 2001-04-16 | 2014-02-11 | Dsm Ip Assets Bv | 多不飽和脂肪酸(pufa)聚乙醯合成酶系統及其用途(三) |
KR101234198B1 (ko) * | 2003-03-26 | 2013-02-19 | 마텍 바이오싸이언스스 코포레이션 | Pufa 폴리케타이드 신타제 시스템 및 이의 용도 |
DE102004017370A1 (de) * | 2004-04-08 | 2005-10-27 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | PUFA-PKS Gene aus Ulkenia |
EP2192170B1 (en) * | 2007-09-04 | 2017-02-15 | Ajinomoto Co., Inc. | Amino acid-producing microorganism and method of producing amino acid |
TW201144442A (en) * | 2010-05-17 | 2011-12-16 | Dow Agrosciences Llc | Production of DHA and other LC-PUFAs in plants |
US11613728B2 (en) * | 2018-08-10 | 2023-03-28 | Kyowa Hakko Bio Co., Ltd. | Microorganism producing eicosapentaenoic acid and method for producing eicosapentaenoic acid |
-
2019
- 2019-08-09 BR BR112021002299-6A patent/BR112021002299A2/pt unknown
- 2019-08-09 WO PCT/JP2019/031649 patent/WO2020032258A1/ja unknown
- 2019-08-09 EP EP19848558.3A patent/EP3835412A4/en active Pending
- 2019-08-09 US US17/266,976 patent/US20210309987A1/en active Pending
- 2019-08-09 CN CN201980053748.9A patent/CN112567019A/zh active Pending
- 2019-08-09 JP JP2020535919A patent/JPWO2020032258A1/ja active Pending
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57134500A (en) | 1981-02-12 | 1982-08-19 | Kyowa Hakko Kogyo Co Ltd | Plasmid pcg1 |
JPS57183799A (en) | 1981-04-17 | 1982-11-12 | Kyowa Hakko Kogyo Co Ltd | Novel plasmid |
JPS5835197A (ja) | 1981-08-26 | 1983-03-01 | Kyowa Hakko Kogyo Co Ltd | プラスミドpcg2 |
JPS58105999A (ja) | 1981-12-17 | 1983-06-24 | Kyowa Hakko Kogyo Co Ltd | 新規ベクタ−プラスミド |
JPS58110600A (ja) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
JPS63233798A (ja) | 1986-10-09 | 1988-09-29 | Kyowa Hakko Kogyo Co Ltd | 5′−グアニル酸の製造法 |
JPS63248394A (ja) | 1987-04-06 | 1988-10-14 | Kyowa Hakko Kogyo Co Ltd | 核酸関連物質の製造法 |
WO1998012343A1 (fr) | 1996-09-17 | 1998-03-26 | Kyowa Hakko Kogyo Co., Ltd. | Procedes de production de nucleotides de sucre et de glucides complexes |
JP2006219528A (ja) | 2005-02-08 | 2006-08-24 | Suntory Ltd | 新規な菌体処理方法を用いた高度不飽和脂肪酸の製造方法 |
WO2008144473A2 (en) | 2007-05-16 | 2008-11-27 | Martek Biosciences Corporation | Chimeric pufa polyketide synthase systems and uses thereof |
JP2011516045A (ja) * | 2008-03-28 | 2011-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ポリケチドシンターゼを使用するジカルボン酸の生成法 |
WO2015025920A1 (ja) * | 2013-08-22 | 2015-02-26 | 協和発酵バイオ株式会社 | アラキドン酸生産ポリケチドシンターゼ及びその利用 |
JP2017184690A (ja) * | 2016-04-08 | 2017-10-12 | 協和発酵バイオ株式会社 | 多価不飽和脂肪酸ポリケチドシンターゼ及びその利用 |
JP2018151233A (ja) | 2017-03-13 | 2018-09-27 | 株式会社東芝 | 放射線測定装置 |
Non-Patent Citations (32)
Title |
---|
"ACOS Lipid Library: PUFA synthase", SCIENCE, vol. 293, 2001, pages 290 - 293 |
"Methods in Enzymology", vol. 185, 1990, ACADEMIC PRESS, article "Gene Expression Technology" |
"Molecular Cloning", 1994, ASM PRESS, article "Methods for GenER domain al and Molecular Bacteriology" |
ACAD. SCI. USA, vol. 90, 1993, pages 5873 |
ANN. REV. BIOCHEM., vol. 52, 1983, pages 537 - 579 |
ANNU. NUTR. METABOL., vol. 35, 1991, pages 128 - 131 |
APPL. ENVIRON. MICROBIOL., vol. 75, 2009, pages 5529 - 5535 |
APPL. MICROBIOL. BIOTECHNOL., 2018, pages 847 - 856 |
APPL. MICROBIOL. BIOTECHNOL., vol. 53, 2000, pages 674 - 679 |
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 73, no. 20, 2007, pages 6378 - 6385 |
BIOSCI. BIOTECHNOL. BIOCHEM., vol. 71, 2007, pages 2905 |
BLIGH, E. G.DYER, W. J., CAN. J. BIOCHEM. PHYSIOL., vol. 37, 1959, pages 911 - 917 |
FEBS LETT., vol. 588, no. 21, 2014, pages 4032 - 4036 |
FEMS MICROBIOL. LETT., vol. 295, 2009, pages 170 - 176 |
HAYASHI ET AL., SCI. REP., vol. 6, 2016, pages 35441 |
HAYASHI, S. ET AL.: "Control Mechanism for Carbon - Chain Length in Polyunsaturated Fatty - Acid Synthesis", ANGEWANDTE CHEMIE , INTERNATIONAL EDITION, vol. 58, 4 March 2019 (2019-03-04), pages 6605 - 6610, XP055685808 * |
HAYASHI, S. ET AL.: "Enhanced production of polyunsaturated fatty acids by enzyme engineering of tandem acyl carrier proteins", SCIENTIFIC REPORTS, vol. 6, 18 October 2016 (2016-10-18), pages 35441, XP055373222 * |
J. AM. CLIN. NUTR., vol. 13, 1994, pages 658 - 664 |
J. MOL. BIOL., vol. 215, 1990, pages 403 |
KEATINGE-CLAY, A.: "Crystal Structure of the Erythromycin Polyketide Synthase Dehydratase", JOURNAL OF MOLECULAR BIOLOGY, vol. 384, 11 October 2008 (2008-10-11), pages 941 - 953, XP025744856, DOI: 10.1016/j.jmb.2008.09.084 * |
KORETARO TAKAHASHI, JOURNAL OF JAPAN OIL CHEMIST'S SOCIETY, vol. 40, 1991, pages 931 - 941 |
METHODS ENZYMOL., vol. 183, 1990, pages 63 |
MOL. MICROBIOL., vol. 55, 2005, pages 137 |
NUCLEIC ACIDS RES., vol. 16, 1988, pages 6127 |
PLANT PHYSIOL. BIOCHEM., vol. 47, 2009, pages 472 - 478 |
PLOS ONE, vol. 6, 2011, pages e20146 |
PLOS ONE, vol. 6, no. 5, 2011 |
PROC. NATL. ACAD. SCI. USA, vol. 69, 1972, pages 2110 |
PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 4306 |
PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 6641 - 6645 |
SCIENTIFIC REPORTS, vol. 6, 2016 |
See also references of EP3835412A4 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2020032258A1 (ja) | 2021-08-12 |
EP3835412A1 (en) | 2021-06-16 |
EP3835412A4 (en) | 2022-05-11 |
US20210309987A1 (en) | 2021-10-07 |
CN112567019A (zh) | 2021-03-26 |
BR112021002299A2 (pt) | 2021-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230235271A1 (en) | Microorganism producing eicosapentaenoic acid and method for producing eicosapentaenoic acid | |
CN105492616A (zh) | 使用含有可通过丙酸盐诱导的ilvbn操纵子的重组棒杆菌生产L-亮氨酸、L-缬氨酸、L-异亮氨酸、α-酮异戊酸、α-酮-β-甲基戊酸或α-酮异己酸的方法 | |
Ujihara et al. | Identification of a novel type of polyunsaturated fatty acid synthase involved in arachidonic acid biosynthesis | |
JP6816970B2 (ja) | 多価不飽和脂肪酸ポリケチドシンターゼ及びその利用 | |
US9574215B2 (en) | Production of fatty acids by heterologous expression of gene clusters from myxobacteria | |
WO2020032258A1 (ja) | 多価不飽和脂肪酸を生産する微生物及び多価不飽和脂肪酸の製造法 | |
US10968437B2 (en) | Factors for the production and accumulation of polyunsaturated fatty acids (PUFAs) derived from PUFA synthases | |
JPWO2008090873A1 (ja) | ポリヒドロキシアルカノエートの製造方法 | |
JP6619229B2 (ja) | アラキドン酸生産ポリケチドシンターゼ及びその利用 | |
US20150322467A1 (en) | Method for optimizing production of eicosapentaenoic acid (epa) in a recombinant host | |
EP3302032B1 (en) | Production of polyunsaturated fatty acids (pufas) using a novel modular docosahexaenoic acid (dha) synthase | |
EP3844269A1 (en) | Production of non-native monounsaturated fatty acids in bacteria | |
AU2022344719A1 (en) | Recombinant microorganism used for producing cdp-choline, and method for producing cdp-choline using said recombinant microorganism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19848558 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020535919 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021002299 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019848558 Country of ref document: EP Effective date: 20210310 |
|
ENP | Entry into the national phase |
Ref document number: 112021002299 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210208 |